Overview

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Status:
Recruiting
Trial end date:
2026-12-15
Target enrollment:
Participant gender:
Summary
This is a single center non-blinded randomized multi-cohort non-comparative phase II trial with a Simon's two-stage design.
Phase:
Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Cisplatin
Doxorubicin
Liposomal doxorubicin
Nivolumab